RPL17 and breast carcinoma: In a trial with 17 women who had metaplastic breast cancer and had already tried several treatments, the combination therapy with nivolumab (a PD-1 inhibitor) and ipilimumab (a CTLA-4 inhibitor) resulted in an overall response rate of 18% [13].